Crohn's disease (CD), Fibrotic hypersensitivity pneumonitis (FHP), Idiopathic inflammatory myopathy (IIM), Idiopathic pulmonary fibrosis (IPF), Systemic sclerosis (SSc), Ulcerative colitis (UC), Unclassifiable interstitial lung disease (uILD)
Conditions
Brief summary
Detection of areas with enhanced 68Ga-FAPi uptake in organs of patients with IBD, CTD or ILD and correlation of imaging outcomes to cellular and serum FAP expression levels, Transcriptome and proteome analysis of tissue samples for FAP and other potential fibrotic biomarkers as well as regulators of upstream signaling pathways and immune cell markers.
Detailed description
Visual and semi-quantitative evaluation of the pharmacokinetics of 68GA-FAPi in patients with CTD and ILD., Optimization of the 68Ga-FAPi PET/CT scanning protocol for patients with CTD and ILD.
Interventions
DRUG68Ga-FAPI-46
Sponsors
Amsterdam UMC Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of areas with enhanced 68Ga-FAPi uptake in organs of patients with IBD, CTD or ILD and correlation of imaging outcomes to cellular and serum FAP expression levels, Transcriptome and proteome analysis of tissue samples for FAP and other potential fibrotic biomarkers as well as regulators of upstream signaling pathways and immune cell markers. | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual and semi-quantitative evaluation of the pharmacokinetics of 68GA-FAPi in patients with CTD and ILD., Optimization of the 68Ga-FAPi PET/CT scanning protocol for patients with CTD and ILD. | — |
Outcome results
None listed